Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 254

The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.

Lung Cancer Biomarkers

Open access
Villalobos, Pamela, Wistuba, Ignacio I. · 2017 · Hematology/Oncology Clinics of North America

Abstract

Synopsis The molecular characterization of lung cancer has considerably changed the classification and treatment of these tumors, becoming an essential component of pathologic diagnosis and oncologic therapy decisions. Through the recognition of novel biomarkers, such as epidermal growth factor receptor mutations and anaplastic lymphoma kinase translocations, it has been possible to identify subsets of patients who benefit from targeted molecular therapies. The success of targeted anticancer therapies and new immunotherapy approaches has created a new paradigm of personalized therapy and has also led to accelerated development of new drugs for lung cancer treatment. This review focuses on clinically relevant cancer biomarkers as targets for therapy, as well as potential new targets for drug development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.hoc.2016.08.006

Cites

95 of 95 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 95 references

Cited by

See all 254

Metadata

Authors
Villalobos, P., & Wistuba, I. I.
Venue
Hematology/Oncology Clinics of North America
Publisher
Elsevier BV
Published
2017-02
Volume
31
Issue
1
Pages
13-29
ISSN
0889-8588 (ISSN-L)
OpenAlex
W3021050361
Cited by
254
References
95
FWCI
7.94
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lung Cancer Biomarkers. https://app.cochat.ai/papers/10.1016/j.hoc.2016.08.006
The paper
Villalobos, P., & Wistuba, I. I. (2017). Lung Cancer Biomarkers. Hematology/Oncology Clinics of North America. https://doi.org/10.1016/j.hoc.2016.08.006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.